EE159 Cost Effectiveness of Pembrolizumab Combined with Chemotherapy Vs. Chemotherapy As First-Line Treatment for Metastatic TNBC That Expresses PD-L1 in the United States
Abstract
Authors
M Huang P Fasching A Haiderali W Pan E Gray J Zhou PH Hu C Le Bailly De Tilleghem N Cappoen M Chaudhuri J O'Shaughnessy